Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEugène BrailovskiXWXia WuCWChristopher Wanjiku

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds venetoclax-based regimens improve hematologic response in relapsed light chain amyloidosis patients, highlighting treatment challenges.

Key Points

  • To define the effectiveness of second-line therapies for patients with light chain amyloidosis after initial daratumumab treatment.
  • Retrospective cohort study of AL amyloidosis patients after upfront daratumumab therapy.
  • Hematologic responses measured using International Society of Amyloidosis criteria.
  • Logistic regression identified predictors for second-line therapy needs.
  • 28% of patients required second-line therapies after D-VCd treatment.
  • 34% of those receiving venetoclax-based regimens achieved a complete response.
  • Patients with alternative regimens exhibited poorer responses, indicating a treatment gap.

Cite This Study

Brailovski et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e03bhttps://doi.org/10.1182/blood-2025-5746
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis2026 · 2 citations
  2. 2Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)2025
  3. 3Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.2024 · 2 citations
  4. 4Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<scp>DVD</scp>) in relapsed/refractory light chain amyloidosis (<scp>AL</scp>) after initial Bortezomib‐based regime2024 · 1 citations
  5. 5A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide2025 · 2 citations